We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Safety Board Allows Merck's Arcoxia Trials to Continue
Safety Board Allows Merck's Arcoxia Trials to Continue
June 23, 2005
Merck’s two clinical studies examining the safety of its yet-to-be-approved Cox-2 inhibitor Arcoxia are allowed to continue following a recent meeting of a Data Safety Monitoring Board (DSMB) responsible for overseeing the trials.